Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China · Delayed Price · Currency is CNY | Market Cap | 367.57B +18.9% |
| Revenue (ttm) | 32.56B +11.6% |
| Net Income | 8.12B +18.7% |
| EPS | n/a |
| Shares Out | 6.62B |
| PE Ratio | 45.27 |
| Forward PE | 39.62 |
| Dividend | 0.20 (0.36%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 90,311,952 |
| Average Volume | 63,740,187 |
| Open | 55.38 |
| Previous Close | 55.38 |
| Day's Range | 54.80 - 57.35 |
| 52-Week Range | 48.88 - 74.04 |
| Beta | 0.21 |
| RSI | 46.41 |
| Earnings Date | Aug 20, 2026 |
About SHA:600276
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China. [Read more]
Financial Performance
In 2025, SHA:600276's revenue was 31.63 billion, an increase of 13.02% compared to the previous year's 27.98 billion. Earnings were 7.71 billion, an increase of 21.69%.
Financial StatementsNews
Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy
A company set up to develop Hengrui Pharma's weight-loss drugs has made a strong debut on the U.S. equity market, building confidence in the "NewCo" business model image credit: Bamboo Works Key Takea...